Anti-Alpha-Synuclein Antibody Formulation for Stable, Low-Viscosity Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable ways to confirm target engagement of monoclonal antibodies with low-abundance pathological alpha synuclein species in CSF and plasma, hindering the establishment of effective dosing regimens for treating synucleinopathies.
Innovation Solution
Development of specific dosing regimens for monoclonal anti-alpha synuclein antibodies based on complex modeling, ensuring target engagement with pathological alpha synuclein species in CSF, using stable and low viscosity liquid pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to treat synucleinopathies, then therapeutic efficacy is improved, but formulation stability and viscosity control become challenging
Solution Approach 1:
The patent applies parameter changes by optimizing formulation conditions including pH (5.0-7.0), temperature (2-8°C storage), ionic strength, and excipient concentrations to maintain antibody stability and achieve low viscosity (5-50 cP) while preserving therapeutic efficacy against synucleinopathies
Solution Approach 2:
The patent uses composite materials by combining monoclonal antibodies with multiple excipients including buffering agents (histidine, phosphate), tonicity agents (sucrose, mannitol), and surfactants (polysorbate 80, poloxamer 188) to create a stable liquid formulation that maintains both therapeutic activity and physical stability
2Measurement precision
If complex modeling is used to establish dosing regimens, then target engagement with pathological alpha synuclein is ensured, but development time and complexity increase
Solution Approach 1:
The patent applies feedback by using complex modeling that incorporates pharmacokinetic and pharmacodynamic parameters to predict and optimize dosing regimens, ensuring target engagement with pathological alpha synuclein while adjusting for individual patient variability and achieving precise therapeutic effects
Solution Approach 2:
The patent applies preliminary action by conducting extensive preclinical studies and complex modeling before clinical implementation to establish optimized dosing regimens, thereby ensuring target engagement and therapeutic efficacy while reducing uncertainty in clinical trials
3Ease of operation
If liquid pharmaceutical compositions are formulated for antibody administration, then ease of administration is improved, but maintaining low viscosity and stability becomes difficult
Solution Approach 1:
The patent applies parameter changes by carefully controlling formulation parameters including pH (5.0-7.0), ionic strength, temperature (2-8°C), and excipient ratios to achieve optimal balance between low viscosity (5-50 cP) for ease of administration and long-term stability during storage and shelf life
Data Source
AI summary
The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.